The impacts of serum iron parameters and/or radiological evidence of systemic iron overload on the prognosis of hematopoietic stem cell transplantation (HSCT) in acute leukemia are controversial. Unfortunately, some of the studies evaluating iron overload in transplant setting did not precisely show the patients with iron overload, mainly due to ignoring consideration of transferrin saturation along with hyperferritinemia for elimination of non-iron overload etiologies of hyperferritinemia. The aim of this study is to assess the effect of iron overload on transplantation related complications and prognosis in acute leukemia. Patients who undergone allogeneic HSCT for acute leukemia in Hacettepe University Medical School Department of Hematology were screened retrospectively in order to find cases with serum iron tests within 9 months before transplant. The endpoints investigated were overall and disease-free survivals, acute and chronic graft-versus-host disease and veno-oclussive disease (VOD). There were 84 patients suitable for inclusion. When various ferritin plus transferrin saturation (TS) cut-off values were investigated for a possible relationship with major transplant-related complications/results only ferritin> 2000 plus TS> 45% was found to have an association with VOD at borderline significance (p= 0.067). In conclusion, we observed a non-significant borderline relationship between iron overload and post-transplant VOD. We did not confirm other post-transplant complications reported in the literature. It must be noticed that although many studies intended to investigate the relationship between iron status and transplant outcomes, only a few of them have really looked for the effect of iron overload.
INTRODUCTION
The impacts of serum iron parameters and/or radiological evidence of systemic iron overload on the prognosis of hematopoietic stem cell transplantation (HSCT) in acute leukemia are controversial. 1, 2 Patients with hematologic malignancies commonly have an elevated serum ferritin prior to HSCT. However, the relationship between serum ferritin and parenchymal iron overload in leukemic patients may not be correlated. 3 Nevertheless, albumin, ferritin, and peripheral blood counts broadly capture health status in patients undergoing allogeneic HSCT. 4 Iron overload or hyperferritinemia irrespective of body iron status may have detrimental effects on the transplantation procedures. [5] [6] [7] [8] Iron overload is associated with free radical generation leading to tissue damage. 9 There is also a possibility that the adverse prognostic impact of pre-transplant hyperferritinemia might be ascribed to other precipitating factors in addition to the iron overload. [10] [11] [12] [13] [14] Reduced intensed toxicity conditioning regimens may attenuate the impact of iron overload related end-organ toxicity when compared to the myeloablative conditioning. [15] [16] [17] [18] Iron overload may predispose to a higher rate of infections associated with transplantation. [19] [20] [21] [22] [23] Stem cell sources, distinct diseases and different protocols may also affect the impact of iron overload on the process of transplantation. [24] [25] [26] [27] [28] Unfortunately, some of the studies evaluating iron overload in transplant setting did not precisely show the patients with iron overload, mainly due to ignoring consideration of transferrin saturation along with hyperferritinemia for elimination of non-iron overload etiologies of hyperferritinemia (Table 1) . Consequently, there are limited (and conflicting) data on the effect of adequatelydefined iron overload on prognosis of allogeneic HSCT. The aim of this study is to assess the effect of iron overload on transplantation related complications and prognosis in acute leukemia.
PATIENTS AND METHODS
Patients who undergone allogeneic HSCT for acute leukemia between years 2004-2014 in Hacettepe University Medical School Department of Hematology were screened retrospectively in order to find cases with serum iron tests within 9 months before transplant. Serum iron (SI), total iron binding capacity (TIBC) and ferritin levels had been measured. TS was calculated by dividing SI level to TIBC. Serum iron tests compatible with iron loading were defined as association of elevated TS (>45%) and ferritin (>500 ng/ml) levels. Various elevated ferritin and transferrin saturation cut-offs were evaluated for a possible association with clinical endpoints. The endpoints investigated were overall and disease-free survivals, acute and chronic graft-versus-host disease (GVHD) and veno-occlusive disease (VOD). Exclusion criteria included less than complete remission of acute leukemia and chronic or acute liver diseases or other important co-morbidities which are expected to affect serum iron tests, veno-occlusive or GVHD risks. Patients with serum iron tests that had been measured within 1 month before any infectious/inflammatory condition were also excluded. Donors were HLA full-matched siblings and stem cell source was peripheral blood in all patients. For GVHD prophylaxis cyclosporine A (CsA) (3 mg/kg/day iv) and methotrexate (MTX) (10 mg/kg/day iv on days 1, 3, 5, 11) were started. CsA was started on the day 0 with the target blood level of 200-300 ng/mL and it was tapered after second months of transplantation according to GVHD status of the patient. 
Statistical Analyses
Numerical and categorical data were expressed as mean ± standard deviation or median (range) and percentage ration, respectively. Categorical and continuous data were compared by the Chi-square (or Fisher's Exact test if required by sample size) and Independent-samples T-test, respectively. Survival analyses were computed by the Kaplan-Meier method. OS was calculated from date of transplan- 
RESULTS
There were 84 patients suitable for inclusion. 48 patients had acute myeloid leukemia whereas 36 patients had acute lymphoblastic leukemia. The mean transferrin saturation for all patients was 42.3% and the median follow-up time for all patients was 39 months. Important baseline characteristics are presented in Table 2 . 67 patients underwent nonmyeloablative HSCT, whereas 17 patients underwent myeloablative HSCT. 4, 17 and 19 patients were encountered VOD, acute and chronic GVHD, respectively. 49.8% and 51.7% were the percentages for all patients at 5 years for DFS and OS, respectively. Different elevated ferritin and transferrin saturation cut-off points were tried in order to find the point which has relationship with clinical results. When various ferritin plus TS cut-off values presented in Table 3 Table 4 .
DISCUSSION
The importance of iron overload in the HSCT setting had been extensively investigated in patients with thalassemia. Inadequate chelation history was found to be an important prognostic factor along with liver fibrosis and hepatomegaly. Also ferritin was suggested as a screening and monitoring tool for iron overload in thalassemia patients. 29 An important difference between acute leukemia and thalassemia regarding consequences of iron overload is that acute leukemia has a much shorter disease duration which is generally insufficient to observe the clinical consequences of iron overload. Iron overload has also been suggested to play an important role in transplantation outcome for the patients with acute leukemia or myelodysplastic syndromes (MDS), as it does in thalassemia. 10 Iron overload prior to transplant has been suggested to predispose to a higher rate of lethal infections. 19, 23 International Journal of Hematology and Oncology A higher threshold of pre-transplant serum ferritin levels may predict HSCT outcomes. 27 Pretransplantation serum ferritin may have significant prognostic value in patients with MDS undergoing myeloablative allogeneic HSCT, inducing a significant increase of non-relapse mortality. 5 Thus, iron status could be considered in transplantation decision-making in MDS. Iron burden might influence toxic-infectious complications during the first 3 months after transplant in auto-transplanted patients. 7 In a previous study, ferritin> 685 ng/ mL was associated with a higher incidence of relapse (p= 0.005) and non-relapse mortality (NRM) (p< 0.001), but not of non-relapse mortality (p= 0.23). 30 Severe iron overload is associated with HSCT-related deaths and invasive aspergillosis. 8 Ferritin and TS >100% at conditioning may increase in toxic deaths after HSCT. 9 When compared with myeloablative regimens, RIC regimens may attenuate the impact of iron overload related end-organ toxicity. 15 The adverse impact of elevated ferritin on NRM and survival was despite its association with lower incidences of acute and chronic GVHD, which are major causes of NRM. 16 Elevation of ferritin at 1 year after SCT, which may reflect transfusion and the development of chronic GVHD, may have an aggravating influence on outcomes after SCT. 21 Regarding studies about iron overload in acute leukemia transplant setting, only ferritin level was used to detect iron overload in many studies. However, ferritin is an insufficient surrogate for iron overload. 11 There are many conditions associated with increased serum ferritin level such as inflammation, infection, macrophage activation, liver injury, and others. Therefore, an increased ferritin level should not be considered as iron overload by itself. In some studies serum albumin level was used to eliminate the ferritin elevation as an acute phase reactant. 4, 10, 15, 32 There is a possibility that the adverse prognostic impact of pre-HSCT hyperferritinemia may be related to factors independent of iron overload. 12, 31 The laboratory sign of iron overload is ferritin elevation in the presence of increased transferrin saturation.
As shown in Table 1 , only two studies aiming to investigate the impact of iron overload by using serum iron tests have considered transferrin saturation. Iron overload was investigated by radiological tests in some studies. Although this method is an optimal one in apparent iron overload, it might miss iron overload in early stages. Liver biopsy was also done in one study. 8 In sum, we found 5 studies which investigated the association between iron overload and post-transplant prognosis using an acceptable method (i.e. serum TS plus ferritin and/or radiological tests and/or liver biopsy) to define iron overload. 1, 2, 3, 8, 12 Some of them found a relationship between iron overload and post-transplant survival. 2, 3 On the other hand some others did not. 1, 12 Interestingly the relationship between iron overload and VOD, probably the most expected specific transplant complication in patients with liver injury, was not reported in any of these studies considered to have adequate methodologies for detection of iron overload. Serum ferritin levels are being used in various clinical conditions. 33, 34 Also there have been some studies that were designed to search effect of hyperferritinemia irrespective of body iron status. These studies are not directly related to this study and they should be considered separately.
In conclusion, we observed a possible non-significant borderline relationship between iron overload and post-transplant veno-occlusive disease. We did not confirm other post-transplant complications reported in the literature. It must be noticed that although many studies intended to investigate the relationship between iron status and transplant outcomes, only a few of them have really looked for the effect of iron overload. Note: Total 14 patients satisfy the condition of "ferritin > 2000 and TS > 45%" in our study. These patients were investigated for associations with major transplant complications.
Abbreviations: GVHD= graft versus host disease, VOD= venoocclusive disease
